A feasibility study of sequential Anthracycline-based regimen and Nab-Paclitaxel / Trastuzumab followed by Trastuzumab as postoperative adjuvant chemotherapy for Her2 positive breast cancer.(SBCCSG-22)
Phase 2
- Conditions
- Primary breast cancer
- Registration Number
- JPRN-UMIN000006085
- Lead Sponsor
- Saitama Breast Cancer Clinical Study Group(SBCCSG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- Female
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1) Pregnant or lactation women. 2) History of other malignancies within the last 5 years. 3) History of bilateral breast cancer 4) History of serious allergy 5) Serious cardiac disfunction 6) Patients judged by the investigator to be unfit to be enrolled into the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Feasibility
- Secondary Outcome Measures
Name Time Method Safety Overall survival Disease free survival Relation between Relative Dose Intensity (RDI) of Nab-Paclitaxel and Disease Free Survival ratio